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ABSTRACT 
Aims 
To identify pre-treatment risk factors for the development of Palmar Plantar 
Erythrodysesthesia in participants receiving capecitabine monotherapy.  Specifically the 
hypothesis that avoidance of activities that cause friction and pressure cause Palmar Plantar 
Erythrodysesthesia was tested. 
Background 
Previous literature showed contradictory evidence on the subject of predictors of 
chemotherapy-induced Palmar Plantar Erythrodysesthesia. There is a lack of empirical 
evidence to support the theory that Palmar Plantar Erythrodysesthesia is caused by damage 
to the microcapillaries due to everyday activities that cause friction or pressure to the hands 
or feet.  
Design  
Prospective epidemiological study of risk factors 
Methods 
Prospective data collection. All patients prior to commencing capecitabine monotherapy 
between 11th June 2009 and 31st December 2010, were offered recruitment into the study 
and followed for 6 cycles of treatment (n = 174). Data were collected during semi-structured 
interviews, from participants' diaries, physical examination of the hands and feet and review 
of notes. Data relating to activities that cause friction, pressure or heat were collected. 
Data were analysed using bivariate (chi-square and independent groups Student’s t) tests 
where each independent variable was analysed against Palmar Plantar Erythrodysesthesia.  
Results 
The only variables that were associated with an increased risk of Palmar Plantar 
Erythrodysesthesia were a tendency to have warm hands and pre-existing inflammatory 
disease. 
Conclusions 
This study gives no support for the hypothesis that avoidance of activities that cause friction 
and pressure cause Palmar Plantar Erythrodysesthesia.  
KEYWORDS  
Nursing, Cancer, Epidemiology, Quantitative Approaches, Palmar Plantar Erythrodysesthesia  
SUMMARY STATEMENT 
Why is this research or review needed? 
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• The risk factors for Palmar Plantar Erythrodysesthesia (PPE) are not known. 
• PPE is a serious problem for patients receiving some chemotherapies. 
 
 What are the key findings? 
• PPE  is related to having hot hands. 
• PPE is not related to activities that cause friction or pressure. 
 
 How should the findings be used to influence policy/practice/research/education? 
• Patients probably do not benefit from avoiding activities that cause friction or 
pressure on the hands. 
• Further research is needed to discover the causes of PPE. 
INTRODUCTION 
PPE is a reddening, swelling, numbness and desquamation of the palms of the hands 
or soles of the feet. It is a common side effect of chemotherapy. There are various 
grading systems, the one used here was according to the capecitabine clinical trial 
criteria (Blum et al. 1999) which grades PPE from 1 (least serious) to 3 (most 
serious). Capecitabine is an anti-neoplastic agent. It is a fluoropyrimidine carbamate 
and interferes with RNA processing and protein synthesis. It is converted to 5-
fluorouracil  (5-FU) initially in the liver with the final conversion by the enzymes 
cytidine deaminase and thymidine phosphorylase. 5-FU is an antimetabolite and acts 
as a false pyrimidine base (uracil), interfering with the synthesis of DNA by blocking 
the action of the enzyme thymidylate synthetase. 
Background 
Surprisingly unlike other toxicities, PPE had a higher incidence in patients with a good 
performance status (Chiara et al. 1997, Abushullaih et al. 2002). Age and gender have been 
suggested as risk factors for PPE, with some evidence that older, female patients have an 
increased risk of PPE (Meta-Analysis Group in Cancer 1998, Schellens et al. 2005, Chabner 
and Longo 2006), while others found no significant difference in age and gender 
(Comandone et al. 1993, Chiara et al. 1997, Abushullaih et al. 2002, Feliu et al. 2005, Sun et 
al. 2009). An increased risk of PPE has been reported in older patients and females receiving 
5-FU(Meta-Analysis Group in Cancer 1998), and may be due to a lower capacity to clear 5-FU 
in women (Milano et al. 1992), but not in association with capecitabine  (Abushullaih et al. 
2002, Cassidy et al. 2002). A higher incidence of PPE has been seen in Japanese(Hyodo et al. 
2006) and Korean patients(Yun et al. 2010), but with a lower incidence in grade 3 PPE which 
was also seen in Asian patients compared to other ethnic groups(Haller et al. 2008, Lee et al. 
2008). Weight loss prior to a diagnosis of cancer was linked to an increased in cidence of 
severe PPE compared to those who had not lost weight. This is thought to be due to altered 
response to chemotherapy in patients with weight loss, since even 5% weight loss can alter 
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measurable physiological values such as immune response (Andreyev et al. 1998). Alcohol 
abuse has been associated with the development of PPE in patients receiving 5-FU or 
capecitabine with a suggestion that this group of patients should be prescribed pyridoxine 
from the start of treatment to reduce the severity of PPE (Vukelja et al. 1989). 
Other patient-related factors linked to the development of PPE include; a pre-existing 
peripheral vascular disease, compromised peripheral nervous system - e.g. carpal tunnel 
syndrome(Zimmerman et al. 1995), peripheral neuropathy from previous chemotherapy 
(Palaia et al. 2006), diabetes(Narasimhan et al. 2004, Wilkes et al. 2005),  dermatological 
disorders and previous irradiation therapy (Hood and Reeck 2006). Previous exposure to 
chemotherapy especially if the patient experienced toxicities such as mucositis, diarrhoea 
(Heo et al. 2004, Wagstaff et al. 2003) and neutropenia (Jansman et al. 2000) have been 
linked to the development of PPE. Whether these factors are statistically significant is 
unclear in some of the literature and are mostly based on case reports, and small scale 
studies and would require validation in larger studies.  
Since PPE may result from increased vascularity, pressure and temperature(Arias et al. 1997) 
in the hands and feet, patient risk factors may include strenuous physical activity (Lassere 
and Hoff 2004), trauma and friction caused by normal activities such as walking or grasping 
objects, and long-term alcohol intake(Lassere and Hoff 2004).  
Some studies, predominantly with patients receiving pegylated liposomal doxorubicin, have 
suggested that active cooling reduces the risk of developing PPE(Zimmerman et al. 1994, 
Mangili et al. 2008). Others have found the opposite with an increased incidence of PPE in 
those who used active cooling measures(Tanyi et al. 2009).  
A previous retrospective analysis, undertaken by the first author, of patients  who had 
received oxaliplatin and infusional 5-FU or capecitabine containing regimes between April 
2008 and March 2009 showed the incidence of PPE was higher in those who received 
capecitabine monotherapy 50.3% (n=151) than in those receiving either other capecitabine 
containing regimes (22.9%, n=96) or infusional 5FU (7.6%, n=145). Thus the current study 
focussed on capecitabine monotherapy. 
THE STUDY 
Aims 
To identify pre-treatment risk factors for the development of PPE in participants receiving 
capecitabine monotherapy. Specifically the hypothesis that avoidance of activities that cause 
friction and pressure cause Palmar Plantar Erythrodysesthesia was tested. 
 
Design 
Prospective epidemiological study of risk factors. 
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Sample/Participants 
The sample was drawn from patients commencing capecitabine monotherapy from  June 
2009 to December 2010 from a general hospital in the East Midlands of England.  
The only inclusion criterion was that the patient commenced capecitabine monotherapy in 
the study period. Exclusion criteria included those participants who did not wish to 
participate and those who were unable to speak English where an interpreter was not 
available. Four patients declined but there were no patients excluded because of language 
difficulties. The reason for declining was that participants felt they had too much going on in 
their lives at present without an additional meeting with another health care professional. 
Most (70.2%) of participants were being treated for colorectal cancer, the next most 
common was breast cancer (8.4%). All participants received more than one cycle of 
chemotherapy, unless the treatment was stopped following the first cycle due to severe 
toxicities including PPE (only one participant). 
Data collection 
Variables that are found in the literature to be thought to be related to PPE were collected 
and in particular actions that may cause friction to the hands or feet.  Participants were 
encouraged to complete a symptom diary. Completion varied ranging from those that kept 
no records to those who kept very detailed accounts of what occurred between cycles. 
Participants were questioned about activities such as regular walking, dancing, gardening, 
DIY, playing musical instruments, sewing, knitting and rubbing hands with moisturising 
cream regularly. Data were thus collected during semi-structured interviews, from 
participant’s diaries and physical examination of the hands and feet and notes review.   
Apart from age, body surface area and creatinine, which were continuous data, all variables 
were categorical and most binary. These are shown in Table 1. N.B. many of these variables 
were originally collected in finer granularity (e.g. ethnic group) but due to small numbers 
have been collapsed into two or a few categories.  
Ethical considerations 
Ethical approval was gained from a university ethics committee and from an NHS local ethics 
committee. 
Data analysis 
Data were analysed independently using bivariate (chi-square and independent groups 
Student’s t) tests where each independent variable was analysed against PPE. The variables 
which achieved a p<0.1 were entered into a binary logistic regression model. 
Validity and reliability/Rigour 
Power  of 80% with an effect size of 0.3 (medium) and the significance level of 0.05 were 
used in this study and sample size estimated using G* Power version 3.1 priori analysis 
program(Faul et al. 2007). A sample size of 108 participants was determined for a bivariate 
analysis.  However all variables with a p<0.1 were considered candidate variables for logistic 
regression. 
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RESULTS 
Baseline  
A total of 174 participants of whom 44.8% were male were included in the analysis. There 
was no significant difference between men and women with respect to PPE. The sample 
characteristics are presented in table 2.  
Toxicity 
Fatigue and diarrhoea were the most common adverse side effects. The incidence of toxicity 
is listed in table 3, the figures reflecting the development of multiple toxicities in many 
participants. The incidence of the toxicities was similar except for the development of a rash 
which was infrequent. PPE developed in 93 participants (53.4%) with 74 (42.5%) developing 
PPE during the first three cycles of their treatment.  
Univariate analysis 
The p values  for variables are shown in table 4. Only three variables were significant at 
p<0.1  – cool hands, inflammatory disease and diabetes. 
Logistic regression 
The omnibus tests of model coefficient revealed a chi-square statistic of 10.3 (df, 3) p =0.016 
indicating that the model performs well compared to the baseline model before the 
variables were added. The Hosmer-Lemeshow statistic was applied to the data revealing a 
chi-square statistic of 1.12 (df, 4) p = .89 which indicates that the observed numbers who 
develop PPE are not significantly different from those expected by the model and that the 
overall fit is good. The Nagelkerke R2 (0.089) value shows about 9% of the variation in the 
outcome variable (PPE) is explained by the logistic model and the percentage correctly 
predicted in this model was 58.7% 
The outcome of the logistic regression analysis produced a model containing 2 predictors 
pre existing inflammatory conditions and cool hands, see table 5. 
DISCUSSION 
This research explored numerous potential risk factors of PPE. The findings will add to the 
current evidence of biographical data, performance status(Oken et al. 1982), co-morbidities 
and renal function as risk factors of PPE. Since this is the first time that individual activity 
related factors have been studied, this is the unique contribution made by this research. The 
findings raise questions about the current advice given to patients receiving capecitabine to 
avoid activities that cause friction or exposure to high temperatures. Whilst it is 
acknowledged that the findings need validating by further research they have implications 
for nursing practice. The main findings are that having cool hands is protective and having 
pre-existing inflammatory disease increases risk of PPE.  However the prediction of PPE with 
the logistic regression remains very low with a small amount of variance accounted for by 
the significant variables. 
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The advice to avoid exposure to heat and keeping the hands cool may be considered 
reasonable as cool hands were a protective variable, though whether having cool hands 
implies making hands cool is beneficial is a moot point. All other activities were not 
confirmed statistically as having any association with the development of PPE. Whilst these 
findings will need validating in further large prospective studies, they do suggest that 
avoidance of some activities is unnecessary unless PPE develops. 
Until such a time that the evidence base for avoiding friction or pressure causing activities is 
established, the focus should be on careful monitoring, questioning and assessment. There is 
evidence that early onset of grade 1 PPE results in an increased risk of developing more 
severe PPE in subsequent cycles. Careful questioning of patients to identify PPE developing 
between cycles which has resolved, may identify those who would benefit from early dose 
reduction to avoid delays in treatment due to severe PPE. This is particularly important in 
light of the emerging evidence that PPE may be a marker of efficacy of treatment. This 
would indicate that those who develop PPE and the ones most likely to benefit from 
continuing treatment. 
Another recommendation would be to ensure men receiving agents that are known to cause 
PPE are educated about the possibility of penile and scrotal involvement, giving them 
permission to report this, which, if identified early, may reduce its severity. 
The evidence for strategies to prevent or manage PPE once it develops is weak. The only 
agent that has been subjected to randomised controlled trials is pyridoxine demonstrating 
that the findings cannot support its use to avoid or manage PPE. The use of emollients has 
not been subjected to rigorous testing. However, since one of the early symptoms of PPE is 
dryness and flaking, the use of emollients would seem logical. Since it a safe and 
uncontroversial substance its use can be recommended without ill effects. 
Limitations 
Stratification may have produced different results. However, this would have required a 
much larger sample from which to randomly select subjects from each group.  
Data collection restricted to one geographical site lacks generalisability. Similarly data 
collection restricted to a single chemotherapy agent cannot be generalised to other agents. 
Although, if we accept the notion that there may be different pathophysiological 
mechanisms and risk factors for PPE between different agents, this may in fact be the 
study’s strength. Large scale studies focusing on each different drug would enable 
comparison of data to test commonality or variability. 
CONCLUSION  
Current practice with patients commencing capecitabine involves advising them to avoid 
activities that cause friction, pressure or high temperature. The evidence base for this is 
based on consensus and case reports. There are no previous large studies to validate this 
advice. This study is the first that has tested any association between activities that cause 
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friction, pressure or high temperature and PPE and the data reported here to not support 
this advice. 
The significant variables found, despite considering all those located in the literature, remain 
poor predictors of PPE. We conclude we still do not know what causes PPE but it is unlikely 
to be activities that cause friction. 
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Table 1 Variables 
 
Variable Values 
Age Continuous 
Aim of treatment Adjuvant , Neoadjuvant , Palliative  
Albumin Low, normal (35-55g/L) or high 
Alcohol No/yes 
Alkaline phosphatase Low, normal (40-130 iu/L) or high 
Alanine 
Aminotransferase 
Low, normal (2-53 iu/L) or high 
Bilirubin Low, normal (3-17 umol/L) or high 
Body mass index Underweight < 18.5; Normal weight 18.5-24.9; Overweight 25-29.9; Obesity ≥ 30 
Body surface area Continuous 
 Normal Cool feet No/yes 
Cool hands No/yes 
Creatinine clearance  <50; 50-80;>80 
Creatinine Continuous 
Diabetes No/yes 
Dry skin No/yes 
Employment Working or not 
Ethnicity White/not White 
Regular hand cream No/yes 
Hobbies with friction Any of gardening, DIY/using tools,  Walking, Dancing, Sewing/knitting 
or Other (especially using hands & feet) or not 
Hot water No/yes 
Inflammatory diseases No/yes 
Marital status In a relationship or not   
Metastatic spread No/yes 
Other capecitabine- No/yes 
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induced toxicities 
Performance status  0. Fully active, able to carry on all pre-disease performance 
without restriction 
1. Restricted in physically strenuous activity but ambulatory and 
able to carry out work of a light or sedentary nature, e.g., light 
house work, office work 
2. Ambulatory and capable of all self-care but unable to carry out 
any work activities. Up and about more than 50% of waking 
hours 
3. Capable of only limited self-care, confined to bed or chair 
more than 50% of waking hours 
4. Completely disabled. Cannot carry on any self-care. Totally 
confined to bed or chair 
5. Dead 
Peripheral neuropathy No/yes 
PPE with previous 
chemotherapy 
No/yes 
Previous cancer 
diagnosis 
No/yes 
Previous radiotherapy No/yes 
Peripheral vascular 
disease 
No/yes 
Recent weight loss No/yes 
Skin type Dry or moist/sensitive 
Skin complaint No/yes 
Smoker No/yes 
Start season Summer or winter 
Recent sunburn No/yes 
Sweaty feet No/yes 
Sweaty hands No/yes 
Tumour type Breast, colorectal or other 
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Table 2 Patient characteristics  
Age mean 
 SD 
64.1 
10.8 
Gender  (Male) 
 
44.8% 
Ethnicity      
White 
Non-white 
 
94.2% 
5.8% 
Marital status 
In a relationship 
Not in a relationship 
 
76.4% 
23.6% 
Employment 
Working 
Not working 
 
39.8% 
60.2% 
Tumour site 
Colorectal 
Breast 
Otherc 
 
63.8% 
25.9% 
10.3% 
Metastatic spread  45.1% 
 
PPE with previous 
chemo         
8.0% 
Season start 
Summer 
Winter 
 
48.3% 
51.7% 
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Table 3: Toxicity 
 
 No PPE PPE P value (chi square) 
Diarrhoea 46.9% 49.5% 0.427 
Mucositis 21.0% 40.9% 0.005 
N & V 37.0% 47.3% 0.171 
Rash 3.7% 6.5% 0.414 
Fatigue 43.2% 46.2% 0.689 
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Table 4: Chi-square test for association between variables and development of PPE before 
cycle 4  
Variable P value 
Age 0.141 
Aim of treatment 0.951 
Albumin 0.499 
Alcohol 0.638 
Alkaline phosphatase 0.222 
Alkaline phosphatase 0.651 
Biirubin  0.839 
Body mass index 0.201 
Body surface area 0.538 
Cool feet 0.372 
Cool hands 0.041 
Creatinine clearance 0.709 
Creatinine 0.131 
Diabetes 0.061 
Dry skin 0.442 
Ethnicity 0.238 
Gender 0.718 
Hand cream 0.100 
Hobbies 0.975 
Hot water 0.558 
Inflammatory conditions 0.040 
Jobs 0.907 
Marital status 0.875 
Met astatic spread 0.674 
Performance status  0.355 
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Peripheral neuropathy 0.242 
PPE with previous  chemo 0.190 
Previous  cancer diagnosis 0.230 
Previous  deep X Ray treatment 0.360 
Peripheral vascular disease 0.301 
Recent  weight loss 0.981 
Skin complaints 0.872 
Skin type  0.622 
Smoker 0.742 
Start season 0.824 
Sunburn 0.355 
Sweaty feet 0.338 
Sweaty hands 0.173 
Tumour site 0.400 
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Table 5: Logistic regression output predictors of PPE  
 Odds ratio Lower 95% CI Upper 95% CI Sig. 
Diabetes 0.448 0.156 1.286 0.136 
Inflammatory conditions 2.114 1.016 4.398 0.045 
Cool hands 0.496 0.251 0.980 0.044 
Constant 0.951   0.840 
 
 
